Anti-angiogenic peptides for cancer therapeutics

Current Pharmaceutical Biotechnology

Volumn 12, Issue 8, 2011, Pages 1101-1116

  Rosca, Elena V ^a   Koskimaki, Jacob E ^a   Rivera, Corban G ^a   Pandey, Niranjan B ^a   Tamiz, Amir P ^a   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

Author keywords

Angiogenesis; Animal model; Computational biology; In vitro model; Inhibitor; Peptidomimetics; Tumor; Tumor vasculature

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOGENESIS INHIBITOR; ANGIOTENSIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BOMBESIN; BRADYKININ; CILENGITIDE; COLLAGEN; CXCL1 CHEMOKINE; ENDOSTATIN; FIBRINOGEN; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; LAMININ; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; OGLUFANIDE; PIGMENT EPITHELIUM DERIVED FACTOR; PROPERDIN; SORAFENIB; SUNITINIB; TETRANECTIN; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; TROPONIN; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYCLIZATION; DISEASE COURSE; DRUG ACTIVITY; DRUG BINDING; DRUG CONJUGATION; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; IN VIVO STUDY; INFLAMMATION; KIDNEY CANCER; KRINGLE DOMAIN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MELANOMA; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HUMANS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES;

ANIMALIA;

EID: 79960006764     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111796117300     Document Type: Article

References (129)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl.J.Med., 1971, 285(21), 1182-1186.
2. Folkman, J. Angiogenesis an integrative approach from science tomedicine; Springer: New York, 2010, p. 601.
3. Senger, D. R.; Galli, S. J.; Dvorak, A. M.; Perruzzi, C. A.; Harvey, V. S.; Dvorak, H. F. Tumor cells secrete a vascular permeabilityfactor that promotes accumulation of ascites fluid. Science, 1983,219(4587), 983-985.
4. Leung, D. W.; Cachianes, G.; Kuang, W. J.; Goeddel, D. V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenicmitogen. Science, 1989, 246(4935), 1306-1309.
5. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature,2005, 438(7070), 932-936.
6. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature, 2000, 407(6801), 249-257.
7. Folkman, J., Angiogenesis. Annu. Rev. Med., 2006, 57, 1-18.
8. Schneider, B. P.; Miller, K. D. Angiogenesis of breast cancer. J.Clin. Oncol., 2005, 23(8), 1782-1790.
9. Uzzan, B.; Nicolas, P.; Cucherat, M.; Perret, G. Y. Micro vessel density as a prognostic factor in women with breast cancer: asystematic review of the literature and meta-analysis. Cancer Res.,2004, 64(9), 2941-2955.
10. Weidner, N. The importance of tumor angiogenesis: the evidence continues to grow. Am. J. Clin. Pathol., 2004, 122(5), 675-677.
11. Kut, C.; Mac Gabhann, F.; Popel, A. S. Where is VEGF in thebody? A meta-analysis of VEGF distribution in cancer. Br. J. Cancer,2007, 97(7), 978-985.
12. Hall, K.; Ran, S. Regulation of tumor angiogenesis by the local environment. Front. Biosci., 15, 195-212.
13. Gressett, S. M.; Shah, S. R. Intricacies of bevacizumab-induced toxicities and their management. Ann. Pharmacother., 2009, 43(3),490-501.
14. Iwamoto, F. M.; Abrey, L. E.; Beal, K.; Gutin, P. H.; Rosenblum, M. K.; Reuter, V. E.; DeAngelis, L. M.; Lassman, A. B. Patterns ofrelapse and prognosis after bevacizumab failure in recurrentglioblastoma. Neurology, 2009, 73(15), 1200-1206.
15. Dorrell, M. I.; Aguilar, E.; Scheppke, L.; Barnett, F. H.; Friedlander, M. Combination angiostatic therapy completely inhibits ocularand tumor angiogenesis. Proc. Natl. Acad. Sci. U. S. A., 2007,104(3), 967-972.
16. Nakamura, T.; Matsumoto, K. Angiogenesis inhibitors: from laboratoryto clinical application. Biochem. Biophys. Res. Commun.,2005, 333(2), 289-291.
17. Saladin, P. M.; Zhang, B. D.; Reichert, J. M. Current trends in theclinical development of peptide therapeutics. IDrugs, 2009, 12(12),779-784.
18. Reichert, J. Development trends for peptide therapeutics Periodical [Online], 2008, p. http://www.peptidetherapeutics.org/PTF_Summary_2008.pdf
19. Bhutia, S. K.; Maiti, T. K. Targeting tumors with peptides fromnatural sources. Trends Biotechnol., 2008, 26(4), 210-217.
20. Stevenson, C. L. Advances in peptide pharmaceuticals. Curr.Pharm. Biotechnol., 2009, 10(1), 122-137.
21. Sulochana, K. N.; Ge, R. Developing antiangiogenic peptide drugsfor angiogenesis-related diseases. Curr. Pharm. Des., 2007, 13(20),2074-2086.
22. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A. Integrins inangiogenesis and lymphangiogenesis. Nat. Rev. Cancer, 2008, 8(8),604-617.
23. Oliveira-Ferrer, L.; Hauschild, J.; Fiedler, W.; Bokemeyer, C.; Nippgen, J.; Celik, I.; Schuch, G. Cilengitide induces cellular detachmentand apoptosis in endothelial and glioma cells mediated byinhibition of FAK/src/AKT pathway. J. Exp. Clin. Cancer Res.,2008, 27, 86.
24. Alghisi, G. C.; Ponsonnet, L.; Ruegg, C. The integrin antagonistcilengitide activates alphaVbeta3, disrupts VE-cadherin localizationat cell junctions and enhances permeability in endothelial cells. PLoS One, 2009, 4(2), e4449.
25. Bradley, D. A.; Daignault, S.; Ryan, C. J.; Dipaola, R. S.; Smith, D.C.; Small, E.; Gross, M. E.; Stein, M. N.; Chen, A.; Hussain, M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastaticcastration resistant prostate cancer patients: a randomized phaseII trial by the prostate cancer clinical trials consortium. Invest. NewDrugs.
26. Hariharan, S.; Gustafson, D.; Holden, S.; McConkey, D.; Davis, D.; Morrow, M.; Basche, M.; Gore, L.; Zang, C.; O'Bryant, C. L.; Baron, A.; Gallemann, D.; Colevas, D.; Eckhardt, S. G. Assessmentof the biological and pharmacological effects of the alpha nu beta3and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD121974), in patients with advanced solid tumors. Ann. Oncol.,2007, 18(8), 1400-1407.
27. Reardon, D. A.; Fink, K. L.; Mikkelsen, T.; Cloughesy, T. F.; O'Neill, A.; Plotkin, S.; Glantz, M.; Ravin, P.; Raizer, J. J.; Rich, K. M.; Schiff, D.; Shapiro, W. R.; Burdette-Radoux, S.; Dropcho, E. J.; Wittemer, S. M.; Nippgen, J.; Picard, M.; Nabors, L. B. Randomizedphase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol., 2008, 26(34), 5610-5617.
28. Park, K.; Kim, Y. S.; Lee, G. Y.; Park, R. W.; Kim, I. S.; Kim, S.Y.; Byun, Y. Tumor endothelial cell targeted cyclic RGD-modifiedheparin derivative: inhibition of angiogenesis and tumor growth. Pharm. Res., 2008, 25(12), 2786-2798.
29. Khalili, P.; Arakelian, A.; Chen, G.; Plunkett, M. L.; Beck, I.; Parry,G. C.; Donate, F.; Shaw, D. E.; Mazar, A. P.; Rabbani, S. A. Anon-RGD-based integrin binding peptide (ATN-161) blocks breastcancer growth and metastasis in vivo. Mol. Cancer. Ther., 2006,5(9), 2271-2280.
30. Cianfrocca, M. E.; Kimmel, K. A.; Gallo, J.; Cardoso, T.; Brown, M. M.; Hudes, G.; Lewis, N.; Weiner, L.; Lam, G. N.; Brown, S.C.; Shaw, D. E.; Mazar, A. P.; Cohen, R. B. Phase 1 trial of the antiangiogenicpeptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrinantagonist, in patients with solid tumours. Br. J. Cancer, 2006,94(11), 1621-1626.
31. Stoeltzing, O.; Liu, W.; Reinmuth, N.; Fan, F.; Parry, G. C.; Parikh, A. A.; McCarty, M. F.; Bucana, C. D.; Mazar, A. P.; Ellis, L. M. Inhibition of integrin alpha5beta1 function with a small peptide(ATN-161) plus continuous 5-FU infusion reduces colorectal livermetastases and improves survival in mice. Int. J. Cancer, 2003,104(4), 496-503.
32. Donate, F.; Parry, G. C.; Shaked, Y.; Hensley, H.; Guan, X.; Beck, I.; Tel-Tsur, Z.; Plunkett, M. L.; Manuia, M.; Shaw, D. E.; Kerbel, R. S.; Mazar, A. P. Pharmacology of the novel antiangiogenic peptideATN-161 (Ac-PHSCN-NH2): observation of a U-shaped doseresponsecurve in several preclinical models of angiogenesis andtumor growth. Clin. Cancer Res., 2008, 14(7), 2137-2144.
33. Sudhakar, A.; Sugimoto, H.; Yang, C.; Lively, J.; Zeisberg, M.; Kalluri, R. Human tumstatin and human endostatin exhibit distinctantiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA, 2003, 100(8), 4766-4771.
34. Maeshima, Y.; Yerramalla, U. L.; Dhanabal, M.; Holthaus, K. A.; Barbashov, S.; Kharbanda, S.; Reimer, C.; Manfredi, M.; Dickerson, W. M.; Kalluri, R. Extracellular matrix-derived peptide bindsto alpha(v)beta(3) integrin and inhibits angiogenesis. J. Biol.Chem., 2001, 276(34), 31959-31968.
35. Li, Y. J.; Sun, L. C.; He, Y.; Liu, X. H.; Liu, M.; Wang, Q. M.; Jin, X. M. The anti-tumor properties of two tumstatin peptide fragmentsin human gastric carcinoma. Acta Pharmacol. Sin., 2009, 30(9),1307-1315.
36. Eikesdal, H. P.; Sugimoto, H.; Birrane, G.; Maeshima, Y.; Cooke, V. G.; Kieran, M.; Kalluri, R. Identification of amino acids essentialfor the antiangiogenic activity of tumstatin and its use in combinationantitumor activity. Proc. Natl. Acad. Sci. USA, 2008,105(39), 15040-15045.
37. Thevenard, J.; Floquet, N.; Ramont, L.; Prost, E.; Nuzillard, J. M.; Dauchez, M.; Yezid, H.; Alix, A. J.; Maquart, F. X.; Monboisse, J.C.; Brassart-Pasco, S. Structural and antitumor properties of theYSNSG cyclopeptide derived from tumstatin. Chem. Biol., 2006,13(12), 1307-1315.
38. Thevenard, J.; Ramont, L.; Devy, J.; Brassart, B.; Dupont-Deshorgue, A.; Floquet, N.; Schneider, L.; Ouchani, F.; Terryn, C.; Maquart, F. X.; Monboisse, J. C.; Brassart-Pasco, S. The YSNSGcyclopeptide derived from tumstatin inhibits tumor angiogenesis bydown-regulating endothelial cell migration. Int. J. Cancer, 126(5),1055-1066.
39. Karagiannis, E. D.; Popel, A. S. Identification of novel short peptidesderived from the alpha 4, alpha 5, and alpha 6 fibrils of type IVcollagen with anti-angiogenic properties. Biochem. Biophys. Res.Commun., 2007, 354(2), 434-439.
40. Koskimaki, J. E.; Karagiannis, E. D.; Rosca, E. V.; Vesuna, F.; Winnard, P. T. Jr.; Raman, V.; Bhujwalla, Z. M.; Popel, A. S., Peptidesderived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularizationand suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia, 2009, 11(12), 1285-1291.
41. Koskimaki, J. E.; Karagiannis, E. D.; Tang, B. C.; Hammers, H.; Watkins, D. N.; Pili, R.; Popel, A. S. Pentastatin-1, a collagen IVderived 20-mer peptide, suppresses tumor growth in a small celllung cancer xenograft model. BMC Cancer, 2010, 10, 29.
42. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin:an endogenous inhibitor of angiogenesis and tumorgrowth. Cell, 1997, 88(2), 277-285.
43. Ling, Y.; Yang, Y.; Lu, N.; You, Q. D.; Wang, S.; Gao, Y.; Chen, Y.; Guo, Q. L. Endostar, a novel recombinant human endostatin,exerts antiangiogenic effect via blocking VEGF-induced tyrosinephosphorylation of KDR/Flk-1 of endothelial cells. Biochem.Biophys. Res. Commun., 2007, 361(1), 79-84.
44. Zheng, M. J. Endostatin derivative angiogenesis inhibitors. Chin.Med. J. (Engl), 2009, 122(16), 1947-1951.
45. Wen, Q. L.; Meng, M. B.; Yang, B.; Tu, L. L.; Jia, L.; Zhou, L.; Xu, Y.; Lu, Y. Endostar, a recombined humanized endostatin, enhancesthe radioresponse for human nasopharyngeal carcinoma andhuman lung adenocarcinoma xenografts in mice. Cancer Sci., 2009,100(8), 1510-1519.
46. Tjin Tham Sjin, R. M.; Satchi-Fainaro, R.; Birsner, A. E.; Ramanujam, V. M.; Folkman, J.; Javaherian, K. A 27-amino-acid syntheticpeptide corresponding to the NH2-terminal zinc-binding domain ofendostatin is responsible for its antitumor activity. Cancer Res.,2005, 65(9), 3656-3663.
47. Morbidelli, L.; Donnini, S.; Chillemi, F.; Giachetti, A.; Ziche, M. Angiosuppressive and angiostimulatory effects exerted by syntheticpartial sequences of endostatin. Clin. Cancer Res., 2003, 9(14),5358-5369.
48. Cattaneo, M. G.; Pola, S.; Francescato, P.; Chillemi, F.; Vicentini, L. M. Human endostatin-derived synthetic peptides possess potentantiangiogenic properties in vitro and in vivo. Exp. Cell Res., 2003,283(2), 230-236.
49. Olsson, A. K.; Johansson, I.; Akerud, H.; Einarsson, B.; Christofferson, R.; Sasaki, T.; Timpl, R.; Claesson-Welsh, L. The minimalactive domain of endostatin is a heparin-binding motif that mediatesinhibition of tumor vascularization. Cancer Res., 2004, 64(24),9012-9017.
50. Wickstrom, S. A.; Alitalo, K.; Keski-Oja, J. An endostatin-derivedpeptide interacts with integrins and regulates actin cytoskeleton andmigration of endothelial cells. J. Biol. Chem., 2004, 279(19),20178-20185.
51. Ponce, M. L.; Hibino, S.; Lebioda, A. M.; Mochizuki, M.; Nomizu, M.; Kleinman, H. K. Identification of a potent peptide antagonist toan active laminin-1 sequence that blocks angiogenesis and tumorgrowth. Cancer Res., 2003, 63(16), 5060-5064.
52. Kenny, L. M.; Coombes, R. C.; Oulie, I.; Contractor, K. B.; Miller, M.; Spinks, T. J.; McParland, B.; Cohen, P. S.; Hui, A. M.; Palmieri, C.; Osman, S.; Glaser, M.; Turton, D.; Al-Nahhas, A.; Aboagye, E. O. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD)peptide radioligand 18F-AH111585 in breast cancer patients. J.Nucl.Med., 2008, 49(6), 879-886.
53. Giordano, R. J.; Cardo-Vila, M.; Lahdenranta, J.; Pasqualini, R.; Arap, W. Biopanning and rapid analysis of selective interactive ligands. Nat. Med., 2001, 7(11), 1249-1253.
54. Giordano, R. J.; Cardo-Vila, M.; Salameh, A.; Anobom, C. D.; Zeitlin, B. D.; Hawke, D. H.; Valente, A. P.; Almeida, F. C.; Nor, J. E.; Sidman, R. L.; Pasqualini, R.; Arap, W. From combinatorialpeptide selection to drug prototype (I): targeting the vascular endothelialgrowth factor receptor pathway. Proc. Natl. Acad. Sci. U.S. A., 2010, 107(11), 5112-5117.
55. Lee, T. Y.; Folkman, J.; Javaherian, K. HSPG-binding peptidecorresponding to the exon 6a-encoded domain of VEGF inhibitstumor growth by blocking angiogenesis in murine model. PLoSOne, 2010, 5(4), e9945.
56. Leali, D.; Bianchi, R.; Bugatti, A.; Nicoli, S.; Mitola, S.; Ragona, L.; Tomaselli, S.; Gallo, G.; Catello, S.; Rivieccio, V.; Zetta, L.; Presta, M. Fibroblast Growth Factor 2-antagonist Activity of aLong-Pentraxin 3-derived Antiangiogenic Pentapeptide. J. CellMol. Med., 2009.
57. Alessi, P.; Leali, D.; Camozzi, M.; Cantelmo, A.; Albini, A.; Presta, M. Anti-FGF2 approaches as a strategy to compensate resistanceto anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenicFGF2-antagonist. Eur. Cytokine Netw., 2009, 20(4), 225-234.
58. Santiago, B.; Gutierrez-Canas, I.; Dotor, J.; Palao, G.; Lasarte, J. J.; Ruiz, J.; Prieto, J.; Borras-Cuesta, F.; Pablos, J. L. Topical applicationof a peptide inhibitor of transforming growth factor-beta1 amelioratesbleomycin-induced skin fibrosis. J. Invest. Dermatol.,2005, 125(3), 450-455.
59. Serrati, S.; Margheri, F.; Pucci, M.; Cantelmo, A. R.; Cammarota, R.; Dotor, J.; Borras-Cuesta, F.; Fibbi, G.; Albini, A.; Del Rosso, M. TGFbeta1 antagonistic peptides inhibit TGFbeta1-dependent angiogenesis. Biochem. Pharmacol., 2009, 77(5), 813-825.
60. Bluff, J. E.; Brown, N. J.; Reed, M. W.; Staton, C. A. Tissue factor,angiogenesis and tumour progression. Breast Cancer Res., 2008,10(2), 204.
61. Liu, Y.; Sainz, I. M.; Wu, Y.; Pixley, R.; Espinola, R. G.; Hassan, S.; Khan, M. M.; Colman, R. W. The inhibition of tube formationin a collagen-fibrinogen, three-dimensional gel by cleaved kininogen(HKa) and HK domain 5 (D5) is dependent on Src family kinases. Exp. Cell. Res., 2008, 314(4), 774-788.
62. Stewart, J. M.; Gera, L.; Chan, D. C.; York, E. J.; Simkeviciene, V.; Bunn, P. A., Jr.; Taraseviciene-Stewart, L. Combination cancerchemotherapy with one compound: pluripotent bradykinin antagonists.Peptides, 2005, 26(8), 1288-1291.
63. Juarez, J. C.; Guan, X.; Shipulina, N. V.; Plunkett, M. L.; Parry, G.C.; Shaw, D. E.; Zhang, J. C.; Rabbani, S. A.; McCrae, K. R.; Mazar, A. P.; Morgan, W. T.; Donate, F. Histidine-proline-rich glycoproteinhas potent antiangiogenic activity mediated through thehistidine-proline-rich domain. Cancer Res., 2002, 62(18), 5344-5350.
64. Dixelius, J.; Olsson, A. K.; Thulin, A.; Lee, C.; Johansson, I.; Claesson-Welsh, L. Minimal active domain and mechanism of actionof the angiogenesis inhibitor histidine-rich glycoprotein. CancerRes., 2006, 66(4), 2089-2097.
65. Donate, F.; Juarez, J. C.; Guan, X.; Shipulina, N. V.; Plunkett, M.L.; Tel-Tsur, Z.; Shaw, D. E.; Morgan, W. T.; Mazar, A. P. Peptidesderived from the histidine-proline domain of the histidineproline-rich glycoprotein bind to tropomyosin and have antiangiogenicand antitumor activities. Cancer Res., 2004, 64(16), 5812-5817.
66. Lee, C.; Dixelius, J.; Thulin, A.; Kawamura, H.; Claesson-Welsh, L.; Olsson, A. K. Signal transduction in endothelial cells by the angiogenesis inhibitor histidine-rich glycoprotein targets focal adhesions. Exp. Cell Res., 2006, 312(13), 2547-2556.
67. Santos, R. A.; Campagnole-Santos, M. J.; Baracho, N. C.; Fontes, M. A.; Silva, L. C.; Neves, L. A.; Oliveira, D. R.; Caligiorne, S.M.; Rodrigues, A. R.; Gropen Junior, C. Characterization of a newangiotensin antagonist selective for angiotensin-(1-7): evidence thatthe actions of angiotensin-(1-7) are mediated by specific angiotensinreceptors. Brain Res. Bull., 1994, 35(4), 293-298.
68. Petty, W. J.; Miller, A. A.; McCoy, T. P.; Gallagher, P. E.; Tallant, E. A.; Torti, F. M. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin. CancerRes., 2009, 15(23), 7398-7404.
69. Yi, Z. F.; Cho, S. G.; Zhao, H.; Wu, Y. Y.; Luo, J.; Li, D.; Yi, T.; Xu, X.; Wu, Z.; Liu, M. A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Srcphosphorylation in VEGF-induced human umbilical endothelialcells. Int. J. Cancer, 2009, 124(4), 843-852.
70. Duffy, M. J. The urokinase plasminogen activator system: role inmalignancy. Curr. Pharm. Des., 2004, 10(1), 39-49.
71. Mishima, K.; Mazar, A. P.; Gown, A.; Skelly, M.; Ji, X. D.; Wang, X. D.; Jones, T. R.; Cavenee, W. K.; Huang, H. J. A peptide derivedfrom the non-receptor-binding region of urokinase plasminogenactivator inhibits glioblastoma growth and angiogenesis in vivoin combination with cisplatin. Proc.Natl. Acad. Sci. USA, 2000,97(15), 8484-8489.
72. Guo, Y.; Mazar, A. P.; Lebrun, J. J.; Rabbani, S. A. An antiangiogenicurokinase-derived peptide combined with tamoxifen decreasestumor growth and metastasis in a syngeneic model of breastcancer. Cancer Res., 2002, 62(16), 4678-4684.
73. Krajewska, E.; Lewis, C. E.; Chen, Y. Y.; Welford, A.; Tazzyman, S.; Staton, C. A. A novel fragment derived from the beta chain ofhuman fibrinogen, beta43-63, is a potent inhibitor of activated endothelialcells in vitro and in vivo. Br. J. Cancer, 102(3), 594-601.
74. Santos, R. A.; Simoes e Silva, A. C.; Maric, C.; Silva, D. M.; Machado, R. P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S. V.; Lopes, M. T.; Bader, M.; Mendes, E. P.; Lemos, V. S.; Campagnole-Santos, M. J.; Schultheiss, H. P.; Speth, R.; Walther, T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA, 2003, 100(14), 8258-8263.
75. Hagedorn, M.; Zilberberg, L.; Wilting, J.; Canron, X.; Carrabba, G.; Giussani, C.; Pluderi, M.; Bello, L.; Bikfalvi, A. Domain swappingin a COOH-terminal fragment of platelet factor 4 generatespotent angiogenesis inhibitors. Cancer Res., 2002, 62(23), 6884-6890.
76. Vandercappellen, J.; Liekens, S.; Bronckaers, A.; Noppen, S.; Ronsse, I.; Dillen, C.; Belleri, M.; Mitola, S.; Proost, P.; Presta, M.; Struyf, S.; Van Damme, J. The COOH-terminal peptide of plateletfactor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesisand suppresses B16 melanoma growth in vivo. Mol Cancer Res., 8(3), 322-334.
77. Benny, O.; Kim, S. K.; Gvili, K.; Radzishevsky, I. S.; Mor, A.; Verduzco, L.; Menon, L. G.; Black, P. M.; Machluf, M.; Carroll, R.S. In vivo fate and therapeutic efficacy of PF-4/CTF microspheresin an orthotopic human glioblastoma model. FASEB J., 2008,22(2), 488-499.
78. Karagiannis, E. D.; Popel, A. S. Novel anti-angiogenic peptidesderived from ELR-containing CXC chemokines. J. Cell Biochem.,2008, 104(4), 1356-1363.
79. Griffioen, A. W.; van der Schaft, D. W.; Barendsz-Janson, A. F.; Cox, A.; Struijker Boudier, H. A.; Hillen, H. F.; Mayo, K. H. Anginex,a designed peptide that inhibits angiogenesis. Biochem. J.,2001, 354(Pt 2), 233-242.
80. Mayo, K. H.; Dings, R. P.; Flader, C.; Nesmelova, I.; Hargittai, B.; van der Schaft, D. W.; van Eijk, L. I.; Walek, D.; Haseman, J.; Hoye, T. R.; Griffioen, A. W. Design of a partial peptide mimeticof anginex with antiangiogenic and anticancer activity. J. Biol.Chem., 2003, 278(46), 45746-45752.
81. Arroyo, M. M.; Mayo, K. H. NMR solution structure of the angiostaticpeptide anginex. Biochim. Biophys. Acta, 2007, 1774(5),645-651.
82. Dings, R. P.; Chen, X.; Hellebrekers, D. M.; van Eijk, L. I.; Zhang, Y.; Hoye, T. R.; Griffioen, A. W.; Mayo, K. H. Design of nonpeptidictopomimetics of antiangiogenic proteins with antitumor activities. J. Natl. Cancer Inst., 2006, 98(13), 932-936.
83. Brandwijk, R. J.; Mulder, W. J.; Nicolay, K.; Mayo, K. H.; Thijssen, V. L.; Griffioen, A. W. Anginex-conjugated liposomes for targetingof angiogenic endothelial cells. Bioconjug.Chem., 2007,18(3), 785-790.
84. Amano, M.; Suzuki, M.; Andoh, S.; Monzen, H.; Terai, K.; Williams, B.; Song, C. W.; Mayo, K. H.; Hasegawa, T.; Dings, R. P.; Griffin, R. J. Antiangiogenesis therapy using a novel angiogenesisinhibitor, anginex, following radiation causes tumor growth delay. Int. J. Clin. Oncol., 2007, 12(1), 42-47.
85. Mayo, K. H.; van der Schaft, D. W.; Griffioen, A. W. Designedbeta-sheet peptides that inhibit proliferation and induce apoptosis inendothelial cells. Angiogenesis, 2001, 4(1), 45-51.
86. Good, D. J.; Polverini, P. J.; Rastinejad, F.; Le Beau, M. M.; Lemons, R. S.; Frazier, W. A.; Bouck, N. P., A tumor suppressordependentinhibitor of angiogenesis is immunologically and functionallyindistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA, 1990, 87(17), 6624-6628.
87. Carpizo, D.; Iruela-Arispe, M. L. Endogenous regulators of angiogenesis--emphasis on proteins with thrombospondin--type I motifs. Cancer Metastasis Rev., 2000, 19(1-2), 159-165.
88. Dawson, D. W.; Volpert, O. V.; Pearce, S. F.; Schneider, A. J.; Silverstein, R. L.; Henkin, J.; Bouck, N. P. Three distinct D-aminoacid substitutions confer potent antiangiogenic activity on an inactivepeptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol., 1999, 55(2), 332-338.
89. Reiher, F. K.; Volpert, O. V.; Jimenez, B.; Crawford, S. E.; Dinney, C. P.; Henkin, J.; Haviv, F.; Bouck, N. P.; Campbell, S. C. Inhibitionof tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int. J. Cancer, 2002, 98(5), 682-689.
90. Haviv, F.; Bradley, M. F.; Kalvin, D. M.; Schneider, A. J.; Davidson, D. J.; Majest, S. M.; McKay, L. M.; Haskell, C. J.; Bell, R. L.; Nguyen, B.; Marsh, K. C.; Surber, B. W.; Uchic, J. T.; Ferrero, J.; Wang, Y. C.; Leal, J.; Record, R. D.; Hodde, J.; Badylak, S. F.; Lesniewski, R. R.; Henkin, J. Thrombospondin-1 mimetic peptideinhibitors of angiogenesis and tumor growth: design, synthesis, andoptimization of pharmacokinetics and biological activities. J. Med. Chem., 2005, 48(8), 2838-2846.
91. Rusk, A.; McKeegan, E.; Haviv, F.; Majest, S.; Henkin, J.; Khanna, C. Preclinical evaluation of antiangiogenic thrombospondin-1 peptidemimetics, ABT-526 and ABT-510, in companion dogs withnaturally occurring cancers. Clin.Cancer Res., 2006, 12(24), 7444-7455.
92. Ebbinghaus, S.; Hussain, M.; Tannir, N.; Gordon, M.; Desai, A. A.; Knight, R. A.; Humerickhouse, R. A.; Qian, J.; Gordon, G. B.; Figlin, R. Phase 2 study of ABT-510 in patients with previouslyuntreated advanced renal cell carcinoma. Clin. Cancer Res., 2007,13(22 Pt 1), 6689-6695.
93. Baker, L. H.; Rowinsky, E. K.; Mendelson, D.; Humerickhouse, R.A.; Knight, R. A.; Qian, J.; Carr, R. A.; Gordon, G. B.; Demetri, G.D. Randomized, phase II study of the thrombospondin-1-mimeticangiogenesis inhibitor ABT-510 in patients with advanced soft tissuesarcoma. J. Clin. Oncol., 2008, 26(34), 5583-5588.
94. Nabors, L. B.; Fiveash, J. B.; Markert, J. M.; Kekan, M. S.; Gillespie, G. Y.; Huang, Z.; Johnson, M. J.; Meleth, S.; Kuo, H.; Gladson, C. L.; Fathallah-Shaykh, H. M. A phase 1 trial of ABT-510concurrent with standard chemoradiation for patients with newlydiagnosed glioblastoma. Arch. Neurol., 67(3), 313-319.
95. Karagiannis, E. D.; Popel, A. S. Peptides derived from type Ithrombospondin repeat-containing proteins of the CCN family inhibitproliferation and migration of endothelial cells. Int. J. Biochem.Cell. Biol., 2007, 39(12), 2314-2323.
96. Karagiannis, E. D.; Popel, A. S. A systematic methodology forproteome-wide identification of peptides inhibiting the proliferationand migration of endothelial cells. Proc. Natl. Acad. Sci. USA,2008, 105, 13775-13780.
97. Fortenberry, Y. M.; Brandal, S.; Bialas, R. C.; Church, F. C. ProteinC inhibitor regulates both cathepsin L activity and cell-mediatedtumor cell migration. Biochim. Biophys. Acta, 1800(6), 580-590.
98. Ek, E. T.; Dass, C. R.; Choong, P. F., PEDF: a potential moleculartherapeutic target with multiple anti-cancer activities. Trends Mol.Med., 2006, 12(10), 497-502.
99. Filleur, S.; Nelius, T.; de Riese, W.; Kennedy, R. C. Characterization of PEDF: a multi-functional serpin family protein. J. Cell. Biochem.,2009, 106(5), 769-775.
100. Gong, Q.; Yang, X.; Cai, W.; Gao, G.; Yang, Z. Expression and Purification of Functional Epitope of Pigment Epithelium-Derived Factor in E. coli with Inhibiting Effect on Endothelial Cells. Protein J.
101. Filleur, S.; Volz, K.; Nelius, T.; Mirochnik, Y.; Huang, H.; Zaichuk, T. A.; Aymerich, M. S.; Becerra, S. P.; Yap, R.; Veliceasa, D.; Shroff, E. H.; Volpert, O. V. Two functional epitopes of pigmentepithelial-derived factor block angiogenesis and induce differentiationin prostate cancer. Cancer Res., 2005, 65(12), 5144-5152.
102. Mirochnik, Y.; Aurora, A.; Schulze-Hoepfner, F. T.; Deabes, A.; Shifrin, V.; Beckmann, R.; Polsky, C.; Volpert, O. V. Short pigmentepithelial-derived factor-derived peptide inhibits angiogenesisand tumor growth. Clin. Cancer Res., 2009, 15(5), 1655-1663.
103. Ek, E. T.; Dass, C. R.; Contreras, K. G.; Choong, P. F. PEDFderivedsynthetic peptides exhibit antitumor activity in an orthotopicmodel of human osteosarcoma. J. Orthop.Res., 2007, 25(12),1671-1680.
104. Kern, B. E.; Balcom, J. H.; Antoniu, B. A.; Warshaw, A. L.; Fernandez-del Castillo, C. Troponin I peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects onhuman endothelial cells and on pancreatic cancer. J. Gastrointest.Surg., 2003, 7(8), 961-968; discussion 969.
105. Bajo, A. M.; Schally, A. V.; Groot, K.; Szepeshazi, K. Bombesinantagonists inhibit proangiogenic factors in human experimentalbreast cancers. Br. J. Cancer, 2004, 90(1), 245-252.
106. Kanashiro, C. A.; Schally, A. V.; Cai, R. Z.; Halmos, G. Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anticancer Drugs, 2005, 16(2), 159-165.
107. Martinez, A.; Zudaire, E.; Portal-Nunez, S.; Guedez, L.; Libutti, S.K.; Stetler-Stevenson, W. G.; Cuttitta, F. Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibitionresults in reduction of tumor growth. Cancer Res., 2004, 64(18),6489-6494.
108. Deplanque, G.; Madhusudan, S.; Jones, P. H.; Wellmann, S.; Christodoulos, K.; Talbot, D. C.; Ganesan, T. S.; Blann, A.; Harris, A. L. Phase II trial of the antiangiogenic agent IM862 in metastaticrenal cell carcinoma. Br. J. Cancer., 2004, 91(9), 1645-1650.
109. Paris, D.; Patel, N.; Ganey, N. J.; Laporte, V.; Quadros, A.; Mullan, M. J. Anti-Tumoral Activity of a Short Decapeptide Fragment ofthe Alzheimer's Abeta Peptide. Int. J. Pept. Res. Ther., 16(1), 23-30.
110. Johnson, M.; Zaretskaya, I.; Raytselis, Y.; Merezhuk, Y.; McGinnis, S.; Madden, T. L. NCBI BLAST: a better web interface. Nucleic Acids Res., 2008, 36(Web Server issue), W5-9.
111. Iozzo, R. V. The family of the small leucine-rich proteoglycans:key regulators of matrix assembly and cellular growth. Crit. Rev.Biochem. Mol. Biol., 1997, 32(2), 141-174.
112. Sulochana, K. N.; Fan, H.; Jois, S.; Subramanian, V.; Sun, F.; Kini, R. M.; Ge, R. Peptides derived from human decorin leucine-richrepeat 5 inhibit angiogenesis. J. Biol. Chem., 2005, 280(30), 27935-27948.
113. Fan, H.; Sulochana, K. N.; Chong, Y. S.; Ge, R. Decorin derived antiangiogenic peptide LRR5 inhibits endothelial cell migration byinterfering with VEGF-stimulated NO release. Int. J. Biochem. Cell. Biol., 2008, 40(10), 2120-2128.
114. Colman, R. W.; Jameson, B. A.; Lin, Y.; Johnson, D.; Mousa, S. A.Domain 5 of high molecular weight kininogen (kininostatin) downregulatesendothelial cell proliferation and migration and inhibitsangiogenesis. Blood, 2000, 95(2), 543-550.
115. Chandrasekaran, V.; Ambati, J.; Ambati, B. K.; Taylor, E. W. Molecular docking and analysis of interactions between vascularendothelial growth factor (VEGF) and SPARC protein. J. Mol.Graph. Model, 2007, 26(4), 775-782.
116. Gabb, H. A.; Jackson, R. M.; Sternberg, M. J. Modelling proteindocking using shape complementarity, electrostatics and biochemicalinformation. J. Mol. Biol., 1997, 272(1), 106-120.
117. Moont, G.; Gabb, H. A.; Sternberg, M.J. Use of pair potentialsacross protein interfaces in screening predicted docked complexes. Proteins, 1999, 35(3), 364-373.
118. Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An AllAtom Force-Field for Simulations of Proteins and Nucleic-Acids. J.Comput.Chem., 1986, 7(2), 230-252.
119. Case, D. A.; Cheatham, T. E., 3rd; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. The Amber biomolecular simulation programs. J. Comput.Chem., 2005, 26(16), 1668-1688.
120. Markovic, S. N.; Suman, V. J.; Rao, R. A.; Ingle, J. N.; Kaur, J. S.; Erickson, L. A.; Pitot, H. C.; Croghan, G. A.; McWilliams, R. R.; Merchan, J.; Kottschade, L. A.; Nevala, W. K.; Uhl, C. B.; Allred, J.; Creagan, E. T., A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am. J. Clin.Oncol., 2007, 30(3), 303-309.
121. Hruby, V. Prospects for peptidomimetic drug design. Drug DiscoveryToday, 1997, 2(5), 2.
122. D'Andrea, L. D.; Del Gatto, A.; Pedone, C.; Benedetti, E. Peptide based molecules in angiogenesis. Chem. Biol. Drug. Des., 2006,67(2), 115-126.
123. Kellen, J.; Torchilin, V. Imobilized Enzymes in Medicine; Springer: Berlin, 1991, pp 206.
124. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug. Deliv. Rev.,2001, 46(1-3), 169-185.
125. Mu, Y.; Kamada, H.; Kaneda, Y.; Yamamoto, Y.; Kodaira, H.; Tsunoda, S.; Tsutsumi, Y.; Maeda, M.; Kawasaki, K.; Nomizu, M.; Yamada, Y.; Mayumi, T. Bioconjugation of laminin peptideYIGSR with poly(styrene co-maleic acid) increases its antimetastaticeffect on lung metastasis of B16-BL6 melanoma cells. Biochem.Biophys. Res. Commun., 1999, 255(1), 75-79.
126. Wu, A. M.; Senter, P. D. Arming antibodies: prospects and challenges for immuno conjugates. Nat. Biotechnol., 2005, 23(9), 1137-1146.
127. Meyer, D. L.; Jungheim, L. N.; Mikolajczyk, S. D.; Shepherd, T.A.; Starling, J. J.; Ahlem, C. N. Preparation and characterization ofa beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents. Bioconjug. Chem., 1992, 3(1), 42-48.
128. Mikolajczyk, S. D.; Meyer, D. L.; Starling, J. J.; Law, K. L.; Rose, K.; Dufour, B.; Offord, R. E. High yield, site-specific coupling of N-terminally modified beta-lactamase to a proteolytically derived single-sulfhydryl murine Fab'. Bioconjug. Chem., 1994, 5(6), 636-646.
129. Schnee, J. M.; Runge, M. S.; Matsueda, G. R.; Hudson, N. W.; Seidman, J. G.; Haber, E.; Quertermous, T. Construction and expressionof a recombinant antibody-targeted plasminogen activator. Proc. Natl. Acad. Sci. USA, 1987, 84(19), 6904-6908.